Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (EW), Alcon (ALC) and Elanco Animal Health (ELAN)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Edwards Lifesciences (EW), Alcon (ALC) and Elanco Animal Health (ELAN).
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Edwards Lifesciences (EW)
Citi analyst Joanne Wuensch maintained a Buy rating on Edwards Lifesciences yesterday and set a price target of $101.00. The company’s shares closed last Tuesday at $80.84.
According to TipRanks.com, Wuensch is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Edwards Lifesciences with a $96.56 average price target, which is a 19.8% upside from current levels. In a report issued on April 1, Wolfe Research also upgraded the stock to Buy with a $92.00 price target.
See the top stocks recommended by analysts >>
Alcon (ALC)
In a report released yesterday, Thomas Stephan from Stifel Nicolaus maintained a Hold rating on Alcon. The company’s shares closed last Tuesday at $74.67.
According to TipRanks.com, Stephan is a 2-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alcon with a $96.23 average price target, representing a 28.3% upside. In a report issued on March 23, TipRanks – Anthropic also reiterated a Hold rating on the stock with a CHF63.00 price target.
Elanco Animal Health (ELAN)
In a report released yesterday, Michael Ryskin from Bank of America Securities maintained a Buy rating on Elanco Animal Health, with a price target of $30.00. The company’s shares closed last Tuesday at $22.80.
According to TipRanks.com, Ryskin is a 3-star analyst with an average return of
Elanco Animal Health has an analyst consensus of Strong Buy, with a price target consensus of $29.40.
Read More on EW:
Disclaimer & DisclosureReport an Issue
- Edwards Lifesciences price target lowered to $92 from $94 at Evercore ISI
- Disney upgraded, Nike downgraded: Wall Street’s top analyst calls
- Edwards Lifesciences upgraded to Outperform from Peer Perform at Wolfe Research
- Edwards Lifesciences: TRISCEND II Data and EVOQUE Differentiation Underpin Buy Rating and Long-Term Growth Outlook
- Edwards Lifesciences announces new data on EVOQUE TTVR system
